| Basics |
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
|
| IPO Date: |
July 24, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.09B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.22 | 2.55%
|
| Avg Daily Range (30 D): |
$1.09 | 3.01%
|
| Avg Daily Range (90 D): |
$0.81 | 2.35%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.53M |
| Avg Daily Volume (30 D): |
.8M |
| Avg Daily Volume (90 D): |
.57M |
| Trade Size |
| Avg Trade Size (Sh.): |
75 |
| Avg Trade Size (Sh.) (30 D): |
56 |
| Avg Trade Size (Sh.) (90 D): |
51 |
| Institutional Trades |
| Total Inst.Trades: |
5,822 |
| Avg Inst. Trade: |
$2.34M |
| Avg Inst. Trade (30 D): |
$2.02M |
| Avg Inst. Trade (90 D): |
$2.32M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.19M |
| Avg Closing Trade (30 D): |
$3.59M |
| Avg Closing Trade (90 D): |
$3.51M |
| Avg Closing Volume: |
77.07K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$11.45
|
$-1.93
|
$-1.55
|
|
Diluted EPS
|
$11
|
$-1.93
|
$-1.55
|
|
Revenue
|
$ 40.88M
|
$ 12.46M
|
$ 8.73M
|
|
Gross Profit
|
$ 36.05M
|
$ 10.75M
|
$ 7.64M
|
|
Net Income / Loss
|
$ 650.08M
|
$ -112.02M
|
$ -89.29M
|
|
Operating Income / Loss
|
$ -461.53M
|
$ -127.06M
|
$ -106.63M
|
|
Cost of Revenue
|
$ 4.83M
|
$ 1.7M
|
$ 1.09M
|
|
Net Cash Flow
|
$ -3.65M
|
$ 1.91M
|
$ 2.72M
|
|
PE Ratio
|
3.27
|
|
|
|
|
|
